Ultragenyx Pharma (RARE) PT Lowered to $142 at Stifel, Buy Rating Reiterated
Tweet Send to a Friend
Stifel analyst Dae Gon Ha lowered the price target on Ultragenyx Pharma (NASDAQ: RARE) to $142.00 (from $176.00) while maintaining ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
